Table 3.
Characteristics of patients according to study group
| RAISE group (n = 40) | Conventional group (n = 68) | P value | |
|---|---|---|---|
| Sex (male/female) | 23/17 | 44/24 | 0.54 |
| Age (months) | 29 (16.25–47.75) | 23 (13–51.75) | 0.44 |
| Duration of fever (days) | 5.5 (5–6.75) | 6 (5–8) | 0.21 |
| Frequency of administration of IVIG | 1 (1–1) | 1 (1–2) | 0.11 |
| Acute-phase coronary artery dilation; n (%) | 3 (7.5 %) | 3 (4.41 %) | 0.67 |
| CS; n (%) | 2 (5 %) | 1 (1.47 %) | 0.55 |
| Abdominal symptoms; n (%) | 18 (45 %) | 23 (33.82 %) | 0.31 |
| White blood cell count (/μ L) | 13,250 (11,700–17,200) | 12,700 (10,200–15 100) | 0.057 |
| Absolute neutrophil count (/μ L) | 8547 (7195–11,520) | 7482 (5356–10,086) | 0.057 |
| Serum albumin concentration (g/dL) | 3.7 (3.4–3.9) | 3.7 (3.3–4) | 0.53 |
| Serum total bilirubin concentration (mg/dL) | 0.6 (0.4–0.775) | 0.6 (0.4–0.8) | 1 |
| Serum aspartate aminotransferase (U/L) | 37 (28–80.75) | 29 (22–71) | 0.079 |
| Serum sodium concentration (mmol/L) | 136 (134–138) | 136 (134–137) | 0.12 |
| Serum CRP concentration (mg/dL) | 7.6 (3.0925–12.545) | 6.36 (2.52–11.08) | 0.41 |
| Serum procalcitonin concentration (ng/mL) | 0.8 (0.245–2.5125) | 0.405 (0.1625–6.317) | 0.074 |
| N-terminal pro-brain natriuretic peptide (pg/mL) | 336 (146–811.5) | 510 (130–983.5) | 0.55 |
| Soluble interleukin-2 receptor (U/mL) | 1585 (1087.5–2090) | 1660 (1070–2360) | 0.59 |
| Urinary β 2-microglobulin/creatinine ratio | 19.36 (5.92–151.9) | 21.57 (5.97–130.74) | 0.98 |
| YPT positive group | 6 (15 %) | 5 (7.35 %) | 0.32 |
| High risk patients; n (%) | 10 (25 %) | 19 (27.9 %) | 0.82 |
| High risk YPT positive; n (%) | 2 (5 %) | 1 (1.47 %) | 0.55 |
| High risk patients with CS; n (%) | 2 (20 %) | 1 (5.26 %) | 0.27 |
| High risk, YPT positive, CS; n (%) | 1 (50 %) | 1 (100 %) | 1 |
Values expressed as count (%) for categorical variables and median (IQR) for continuous variables